REAL-WORLD SAFETY AND EFFICACY OF NAB-PACLITAXEL IN PATIENTS WITH METASTATIC BREAST CANCER (MBC) TREATED IN THE UNITED STATES- RESULTS FROM A HEALTH INSURANCE DATABASE

Author(s)

Patt D1, Liang C2, Li L2, Ko A3, Duval Fraser C3, Corzo D4, Enger C5
1McKesson Specialty Health (MSH)/US Oncology (USO), Austin, TX, USA, 2Optum, Waltham, MA, USA, 3Celgene Corporation, Berkeley Heights, NJ, USA, 4Celgene Corporation, Summit, NJ, USA, 5Optum, Ann Arbor, MI, USA

OBJECTIVES: To characterize safety and efficacy outcomes of albumin-bound paclitaxel (nab-paclitaxel) in MBC in the United States since its approval in 2005 using health insurance claims data. METHODS: A retrospective claims analysis was conducted using the Optum Research Database (United Health affiliate). The analysis included females aged ≥ 18 years diagnosed with MBC (≥ 2 claims of BC diagnosis separated by ≥ 30 days and ≥ 2 claims of metastatic spread) prior to nab-paclitaxel initiation who had complete medical coverage and pharmacy benefits, ≥ 6 months of continuous enrollment in a US health insurance plan from January 2005 through September 2012, no other primary malignancy, and no prior nab-paclitaxel therapy. Data were supplemented by Social Security Death Index sources. Cohorts were determined by line of therapy, nab-paclitaxel regimen, and schedule. Descriptive statistics were used to characterize outcomes. Endpoints included time to treatment discontinuation (TTD), overall survival (OS), and safety. RESULTS: Among 664 eligible patients, most were between 40-69 years of age (88%) and had received nab-paclitaxel as ≥ second-line therapy (74%), monotherapy (61%), and weekly (71%). Bevacizumab (22%) and HER2-targeted therapies (9%) were used as combination partners. Median TTD and OS were 6.1 and 17.4 months, respectively. By line of therapy (first, second, and ≥ third), TTD was 7.1, 6.6, and 5.3 months and OS was 22.7, 17.4, and 15.1 months. Median OS was similar when nab-paclitaxel was used in combination or as monotherapy (18.7 and 16.8 months) and weekly or every 3 weeks (18.6 and 17.4 months). No new safety signals were observed. CONCLUSIONS: Outcomes in this real-world patient population were consistent with clinical trial data, affirming the effectiveness and manageable safety profile of nab-paclitaxel in patients with MBC. This analysis will also help evaluate the benefit of nab-paclitaxel in patients aged ≥ 70 years.

Conference/Value in Health Info

2014-05, ISPOR 2014, Palais des Congres de Montreal

Value in Health, Vol. 17, No. 3 (May 2014)

Code

PCN18

Topic

Clinical Outcomes

Topic Subcategory

Comparative Effectiveness or Efficacy

Disease

Oncology

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×